Paysafe Limited (PSFE) disclosed select interim financial and corporate items for the period ending June 30, 2025. The company had 1,600,000,000 shares authorized with 63,527,152 issued and 58,846,732 outstanding as of June 30, 2025 versus 62,511,104 issued and 59,888,304 outstanding at December 31, 2024. There were 53,900,329 public warrants outstanding exercisable at $138.00 per share. The Board authorized an additional $70,000 share repurchase capacity. For the quarter and six months ended June 30, 2025, the company recorded significant restructuring and legal-related costs and reported foreign exchange losses ($5,417 for the quarter; $5,403 for six months) and fair value losses on derivatives. Severance liabilities increased to $1,104 as of June 30, 2025. Management stated compliance with credit facility covenants as of the issuance date. Contingent consideration receivables are measured at fair value using Level 3 discounted cash flows.
Paysafe Limited submitted a Form 6-K to provide investors with a press release announcing its financial condition and results of operations for the quarter ended June 30, 2025. The press release is included as Exhibit 99.1 to the report.
The company notes that this Form 6-K and its exhibit are being furnished, not filed, so they are not subject to certain Exchange Act liabilities and are not automatically incorporated by reference into other U.S. securities law filings unless specifically referenced.
Paysafe Limited (PSFE) Form 144: An affiliate intends to sell 2,149 common shares on or after 21 Jul 2025 via Fidelity on the NYSE. The shares were received through restricted-stock vesting on 18 Jul 2025 and are valued at $29,806.63. With 59,888,304 shares outstanding, the trade equals roughly 0.004 % of the float, implying negligible dilution or price pressure.
The same filer—named Richard Swales in the “Securities Sold During the Past 3 Months” table—previously sold 7,987 shares on 5 Jun 2025 for $100,156.98, bringing disclosed insider sales to 10,136 shares (<0.02 % of outstanding) over the period. The notice states the seller knows no undisclosed adverse information and does not list a Rule 10b5-1 plan adoption date.
Given the small size and routine nature of the transaction, immediate market impact appears minimal, though investors may watch for any uptick in the pace of insider disposals.